Company: LHI
Filing Date: 2025-11-20
Form Type: F-1/A
Source: 0001213900-25-112807
Chunk: 173

Company: Living Homeopathy International Ltd.
Filing Date: 2025-11-20
Form: F-1/A
Chunk 173
---
 and    
 making recommendations to our board of directors on all matters of corporate governance and 
 on any corrective action to be taken; and                                                   |

| ● | monitoring                                                                                
 compliance with our code of business conduct and ethics, including reviewing the adequacy 
 and effectiveness of our procedures to ensure proper compliance.                          |

Code of Business Conduct and Ethics, Insider Trading Policy and Clawback Policy

We have adopted (i) a code of business conduct
and ethics, (ii) an insider trading policy that applies to our directors, officers, and employees, and (iii) a clawback policy that
applies to our directors, officers and employees (collectively, the “Policies”). The Policies will become effective upon
the effectiveness of the registration statement of which this prospectus is a part.

Corporate Governance

We are a “foreign private issuer,” as defined by the SEC. As a result, in accordance with the rules and regulations of Nasdaq, we may at our option comply with home country governance requirements and certain exemptions thereunder rather than complying with Nasdaq corporate governance standards. While we currently intend to voluntarily follow all Nasdaq corporate governance rules, including rules regarding committee structure and director independence, as described above, we mayin the future choose to take advantage of the following exemptions afforded to foreign private issuers:

| ● | Exemption from the requirement                                               
 that a majority of our board of directors consists of independent directors. |

| ● | Exemption from the requirement                                                                                               
 that our audit committee have a written charter addressing the audit committee’s responsibilities and authority as set forth 
 in Nasdaq Rule 5605(c)(1).                                                                                                   |

| ● | Exemption from the requirement                                                                                                
 that our compensation committee have a written charter addressing the remuneration committee’s responsibilities and authority 
 as set forth in Nasdaq Rule 5605(d).                                                                                          |

| ● | Exemption from the requirement                                                                                                             
 to have independent director oversight of director nominations and a formal written charter or board resolution addressing the nominations 
 process as set forth in Nasdaq Rule 5605(e).                                                                                               |

| ● | Exemption from the requirement                                                                                                     
 that we have a code of conduct applicable to all directors, officers and employees and from any requirement that we have a code of 
 conduct in compliance with Section 406 of the Sarbanes-Oxley Act of 2002.                                                          |

| ● | Exemption from the Nasdaq                                                                                                         
 rules applicable to domestic issuers requiring disclosure within four business days of any determination to